Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China
This article was originally published in PharmAsia News
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.
You may also be interested in...
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 2 of 2)
Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.
In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker